Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. - Wikidata - awgldk - TriplyDB

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

http://www.wikidata.org/entity/Q36333522

about

Notch signaling deregulation in multiple myeloma: A rational molecular target Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential Trial Watch: Proteasomal inhibitors for anticancer therapy Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma The resistance mechanisms of proteasome inhibitor bortezomib.Novel approaches to treatment of double-refractory multiple myeloma.PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Why proteasome inhibitors cannot ERADicate multiple myeloma.Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL.A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Overcoming bortezomib resistance in multiple myeloma.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Oral ixazomib maintenance therapy in multiple myeloma.

P2860

Q26797283-BAC77D14-558F-4AB7-BACC-52BCAE51764A Q26822754-9004E43D-476E-44AD-BCC2-8941FEB2EED6 Q27692033-A99DBEF5-16B3-4C66-BBCF-6C1815068C12 Q28075927-7AE30CBB-B31B-4C1E-82AF-05C805B75388 Q28082910-DA6D3579-E37F-4F92-B442-3F72EBA88BCC Q28540339-FF4E1155-B4A7-46CB-A459-92BC329F918F Q28542684-57965267-7D8B-44D5-8315-7270A83C3A5E Q28544663-D1AE6A73-7BF0-42AE-9F0C-1B35C45EB078 Q33585280-2E3FB81F-C497-407B-9749-8DBA67D744B3 Q33701777-D1A6FB15-0B7B-4AAD-A804-8ABF99CAE5BB Q33742779-FAF0966A-EDBE-427D-B885-412E42AD1887 Q33994341-6215E06F-7071-49D7-BA85-B907D17DB0AB Q34256126-C99F9207-563C-46F7-82F7-BFC6EF08003C Q34347172-9B7AB4B8-CF41-40AE-A679-7E1F2A220044 Q34518277-968CA548-F755-47D7-B0F3-0B09B6DD5A99 Q34722352-1DA8B341-8638-4DC4-BAE9-C777F79F6F87 Q34773850-82C50E9B-8181-4A28-8D62-2CED665F7402 Q35024457-8D9EB35D-B155-42B3-80AA-19CA16024714 Q35192691-4AA3A2E3-F935-4234-830D-C5A93BC159DF Q35538460-B2A7F1FC-315A-4B1E-B8A2-0D2154CD850B Q35606589-7BC565B0-207A-4DC2-9EF6-261B8B2D31C6 Q35740455-590E98DC-302A-489D-A6C8-BED5D3322DF8 Q35832168-F9F6B28D-DE59-4686-9501-AF11E86EE512 Q35998168-9A3F3CFD-DE80-403F-95DF-27CB8E364EA4 Q36183770-3A63D77A-3440-4F96-BB8D-626CE6A852D5 Q36335870-04A3CA56-4B6B-40DA-AD64-C523AD623299 Q36444233-7ED4F39F-CFDA-42CA-9D52-B3344CC0305F Q36546004-F0F7DBBC-0B38-470A-8D64-BAD9156681B4 Q36562098-F103DEE4-618C-439B-A799-86237DF255F7 Q36805679-A4E23282-602E-496F-AD69-5028BA85A8BB Q37171812-D80B2A1F-BB2A-4827-BE03-86161234BA36 Q37393383-B393E743-F6EA-431E-AD1F-7E28C4FC68C5 Q37400912-5AE85F78-E59E-4249-B69B-B594DD1E6AC5 Q37435436-DC90DC62-9AE0-462B-ADB2-7014A0992BAF Q37697253-9D7DB6CF-D828-4902-B068-A60C361629A7 Q37701084-DDD0CB48-C0A9-4797-A928-967925F7A5C4 Q38202977-3C31A8FA-1421-4C53-B001-0DBA4B8FB588 Q38238610-9DAE674F-38F5-43E1-A60E-45A5FC9F4B2B Q38427697-951F2880-59D9-45BB-B1E7-8380771834FC Q38640514-3BC6768E-BB3E-416F-8278-85815C0BC66C

P2860

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

http://www.wikidata.org/entity/Q36333522

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Targeting the insulin-like gro ...... al models of multiple myeloma.

@ast

Targeting the insulin-like gro ...... al models of multiple myeloma.

@en

type

label

Targeting the insulin-like gro ...... al models of multiple myeloma.

@ast

Targeting the insulin-like gro ...... al models of multiple myeloma.

@en

prefLabel

Targeting the insulin-like gro ...... al models of multiple myeloma.

@ast

Targeting the insulin-like gro ...... al models of multiple myeloma.

@en

P1433

Q36333522-D50EB41E-71AF-4D9D-AE8A-683D08B1D9A1

P1476

Q36333522-1B51305C-6642-4A38-9050-663681E2E504

P2093

Q36333522-11ED2482-806D-4B72-8F9A-7BAA6663BBD4

Q36333522-7BCAC957-C54C-4E7B-A245-DDCDB502EEFE

Q36333522-95B9C76B-F87F-497A-8128-A074BDC1B615

Q36333522-9882789B-52D6-4BBC-B203-46E89754DB8C

Q36333522-9EB1E64D-E6A5-4A73-9F85-134C6850B760

Q36333522-A1350AE1-60DA-4747-BEBA-747CD5D19B34

Q36333522-A4CF2FFE-5566-4EDB-894F-336CBACBDF78

Q36333522-A9EB0E0C-79ED-463A-84A7-8F487AC35DC5

Q36333522-B23B3BF7-BF17-4B85-A3F1-E1D5D8779914

Q36333522-CD3374E6-BAD7-4F6C-9777-DA37C21F9046

P2860

Q36333522-02DAB305-4B8F-4A89-A1D9-962D7D2D658F

Q36333522-03AA3F91-8FAB-46B0-A7FD-C209145FF4AB

Q36333522-0BF345CC-AB93-488B-BAED-41B31E60D250

Q36333522-123D6686-C898-436D-87AE-6798BE7903BA

Q36333522-30CBE60E-E635-4927-BA9B-725D43C379AF

Q36333522-3102495E-6721-4D6D-8588-8113DC69A2D2

Q36333522-34EC10A8-7903-4CA3-B083-985F8386A576

Q36333522-39F82B45-34C4-4C79-B9E9-EEC836D4571F

Q36333522-3C5BD346-4F64-4D5D-845A-E8A9454F7EB4

Q36333522-3E7DF358-6773-4429-A61D-D01AB560994E

P304

Q36333522-5CFD7028-0D36-45BA-8C2B-2B33C4B9C351

P31

Q36333522-709FCEBE-E262-426B-82F3-D6C8BC31F016

P356

Q36333522-4E8015C6-3B12-4BCA-8A60-651E6E0C8E5C

P407

Q36333522-04F2ADDD-0928-4704-8708-20BE59DF6DF7

P433

Q36333522-EF0DA225-8F1E-493A-BA60-E2F1BA8D2551

P478

Q36333522-7314CF0B-9F8B-4862-B96F-A4A0861DCEA9

P50

Q36333522-68DBD1D0-4323-46DE-A142-380CB282C223

Q36333522-A9D19E9C-B113-44EB-801D-E8087FF3A7AD

P577

Q36333522-83C6569B-03C8-44AA-81AF-112676C9006B

P698

Q36333522-7646C848-2C6B-4E2F-BDA4-B452FA06F97A

P921

Q36333522-AF79369F-2B0C-449F-9418-32CEDA1DFE20

P932

Q36333522-603D3901-6A39-42B2-B01A-18EE7C3A71B4

P356

BLOOD-2011-10-386789

P1433

P1476

Targeting the insulin-like gro ...... cal models of multiple myeloma

@en

P2093

Caimiao Wei

http://www.w3.org/2001/XMLSchema#string

Chad C Bjorklund

http://www.w3.org/2001/XMLSchema#string

Deborah J Kuhn

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Hua Wang

http://www.w3.org/2001/XMLSchema#string

Jatin J Shah

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Pei Lin

http://www.w3.org/2001/XMLSchema#string

R Eric Davis

http://www.w3.org/2001/XMLSchema#string

Richard J Jones

http://www.w3.org/2001/XMLSchema#string

P2860

The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Structure of 20S proteasome from yeast at 2.4 A resolution

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Statistical issues in the analysis of Illumina data.

Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.

A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data.

20S proteasome biogenesis.

Development of the proteasome inhibitor Velcade (Bortezomib).

P304

3260-3270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-10-386789

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2012-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22932796

http://www.w3.org/2001/XMLSchema#string

P921

P932

3476538

http://www.w3.org/2001/XMLSchema#string